New advances in DPYD genotype and risk of severe toxicity under capecitabine

Marie-Christine Etienne-Grimaldi1, Jean-Christophe Boyer2, Christophe Beroud3,4, Litaty Mbatchi5, André van Kuilenburg5,6, Christine Bobin-Dubigeon7, Fabienne Thomas8, Etienne Chatelut9, Jean-Louis Merlin9, Frédéric Pinguet10, Christophe Ferrand11, Judith Meijer6, Alexandre Evrard6, Laurence Llorca1, Gilles Romieu10, Philippe Follana1, Thomas Bachetot12, Loïc Chaigneau11, Xavier Pivot11, Véronique Dieras13, Rémy Largillier14, Mireille Mousseau15, Anthony Goncalves16, Henri Roche6, Jacques Bonneterre17, Véronique Servent17, Nadine Dohollou18, Yann Château1, Emmanuel Chamorey1, Jean-Pierre Desvignes3, David Salgado3, Jean-Marc Ferrero1, Gérard Milano1*

1 Centre Antoine Lacassagne, Nice, France, 2 CHU de Nîmes, Nîmes, France, 3 Aix-Marseille University, INSERM UMR S109, GMGF, Marseille, France, 4 APHM Hôpital Timone, Laboratoire de Génétique Moléculaire, Marseille, France, 5 Faculté de Pharmacie de Montpellier, Montpellier, France, 6 Laboratory Genetic Metabolic Diseases, Academic Medical Center, Amsterdam, The Netherlands, 7 Institut de Cancérologie de l’Ouest, MMS EA 2160, Université de Nantes, Nantes, France, 8 Institut Claudius-Regaud, CRCT, Université de Toulouse, Inserm, UPS, Toulouse, France, 9 Institut de Cancérologie de Lorraine, UMR CNRS 7039 CRAN, Université de Lorraine, Nancy, France, 10 Centre Paul Lamarque, Montpellier, France, 11 CHU de Besançon, Besançon, France, 12 Centre Léon Bérard, Lyon, France, 13 Institut Curie, Paris, France, 14 Centre Azurien de Cancérologie, Mougons, France, 15 CHU de Grenoble, Grenoble, France, 16 Institut Paoli Calmettes, Marseille, France, 17 Centre Oscar Lambret, Lille, France, 18 Polyclinique Nord Aquitaine, Bordeaux, France

* gerard.milano@nice.unicancer.fr

Abstract

Background

Deficiency in dihydrorymidine dehydrogenase (DPD) enzyme is the main cause of severe and lethal fluoropyrimidine-related toxicity. Various approaches have been developed for DPD-deficiency screening, including DPYD genotyping and phenotyping. The goal of this prospective observational study was to perform exhaustive exome DPYD sequencing and to examine relationships between DPYD variants and toxicity in advanced breast cancer patients receiving capecitabine.

Methods

Two-hundred forty-three patients were analysed (88.5% capecitabine monotherapy). Grade 3 and grade 4 capecitabine-related digestive and/or neurologic and/or hematotoxicities were observed in 10.3% and 2.1% of patients, respectively. DPYD exome, along with flanking intronic regions 3’UTR and 5’UTR, were sequenced on MiSeq Illumina. DPD phenotype was assessed by pre-treatment plasma uracil (U) and dihydrouracil (UH2) measurement.

Results

Among the 48 SNPs identified, 19 were located in coding regions, including 3 novel variations, each observed in a single patient (among which, F100L and A26T, both pathogenic in...
Combined analysis of deleterious variants *2A, I560S (*13) and D949V showed significant association with grade 3–4 toxicity (sensitivity 16.7%, positive predictive value (PPV) 71.4%, relative risk (RR) 6.7, p<0.001) but not with grade 4 toxicity. Considering additional deleterious coding variants D342G, S492L, R592W and F100L increased the sensitivity to 26.7% for grade 3–4 toxicity (PPV 72.7%, RR 7.6, p<0.001), and was significantly associated with grade 4 toxicity (sensitivity 60%, PPV 27.3%, RR 31.4, p = 0.001), suggesting the clinical relevance of extended targeted DPYD genotyping. As compared to extended genotype, combining genotyping (7 variants) and phenotyping (U>16 ng/ml) did not substantially increase the sensitivity, while impairing PPV and RR.

Conclusions
Exploring an extended set of deleterious DPYD variants improves the performance of DPYD genotyping for predicting both grade 3–4 and grade 4 toxicities (digestive and/or neurologic and/or hematotoxicities) related to capecitabine, as compared to conventional genotyping restricted to consensual variants *2A, *13 and D949V.

Introduction
Since its launch in 1998, the 5FU oral prodrug capecitabine has gradually become a major drug and is currently considered as a standard of care for advanced breast cancer. Capecitabine is ultimately metabolized by thymidine phosphorylase which produces 5FU at target cell level. Next, intracellularly-produced 5FU enters either the anabolic or the catabolic route. Most 5FU is deactivated into fluorodihydrouracil by ubiquitous dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme of 5FU catabolism, expressed in various human tissues as well as in human cancer cells [1,2]. Consequently, any DPD activity variation within tumor or normal cells may have a major repercussion on availability of 5FU for anabolism, and thus may significantly impact capecitabine pharmacodynamics. DPD deficiency may be considered as the major cause of capecitabine toxicity, and more generally fluoropyrimidine-related toxicity risk [3–6]. Accordingly, the wide inter-patient variability of DPD enzyme activity measured in peripheral blood mononuclear cells (PBMC) is significantly correlated to systemic 5FU clearance in patients receiving i.v. 5FU [3,7]. Of note, breast cancer treatment with capecitabine is particularly concerned since PBMC-DPD activity has been shown to be lower in women as compared to men [7], in line with the observation that women are particularly prone to suffer from fluoropyrimidine toxicity [8]. Importantly, cases of lethal toxicity have been reported in patients with marked DPD deficiency after standard 5FU [9] or capecitabine administration [10–12].

DPD is encoded by DPYD, a large gene spanning 950 kb on chromosome 1p22 (23 exons comprising 4399 nucleotides) [13]. DPD activity is controlled at both transcriptional and post-transcriptional levels. Post-transcriptional regulation of DPD involved microRNAs miR-27a and miR-27b [14]. At transcriptional level, more than 200 polymorphisms have been identified in DPYD coding regions. In vitro studies have demonstrated that only a few DPYD polymorphisms have a significant deleterious impact on enzymatic activity, while even fewer are associated with proficient (i.e. elevated) enzyme activity [15,16]. It has been clearly demonstrated that DPYD deleterious variants *2A (c.1905+1G>A), D949V (c.2846A>T), and *13 (1560S, c.1679T>G) are relevant predictors of fluoropyrimidine-related toxicities [6,17–19]. From a prospective trial conducted on 2594 colon cancer patients receiving adjuvant 5FU-based
chemotherapy [20], the combined sensitivity of the variants ‘2A, ‘13 and D949V to predict grade 3–4 5FU-related toxicity is only 5.3% (33% toxicity, 2.2% of patients carrying a variant). The scarcity of these three DPYD variations explains this very low sensitivity: considering at best 4% of patients carrying one of these three pathological variants and a prevalence of severe toxicity at 10%, a genetic test based on these 3 variants cannot have a sensitivity greater than 40%. One could thus expect to improve sensitivity by identifying additional relevant variants, by combining genotyping and phenotyping approaches, or by focusing on the less frequent, most relevant grade 4 toxicities.

Despite decades of literature data on DPYD pharmacogenetics, very few clinical prospective studies have reported full DPYD exome sequencing in patients treated by fluoropyrimidines [21–24], and most of these studies were based on small population subsets. The French GPCO-Unicancer group recently conducted a prospective observational study on 303 advanced breast cancer patients receiving capecitabine to assess the impact of pre-treatment DPD and CDA phenotype along with a limited number of targeted variants in DPYD (‘2A, ‘13, D949V), TYMS and MTHFR genes, on capecitabine toxicity and efficacy [25]. DPD phenotyping was based on pre-treatment measurement of plasma uracil (U) and dihydrouracil (UH2). We presently report a genomic-based complementary study conducted in 243 patients for whom full sequencing of DPYD exome, along with flanking intronic regions, was performed in order to examine relationships between DPYD variants and both DPD phenotype and severe capecitabine-related toxicity.

**Patients and methods**

**Patients**

This prospective observational study (Eudract 2008-004136-20) was conducted on 303 advanced breast cancer patients included between February 2009 and February 2011 in 15 French institutions. This study was approved by the “Comité de Protection des Personnes—Méditerranée Sud V” (approval number CPP 08.067). Written informed consent was obtained for each patient. Among the 303 initially-included patients, 17 were not allocated to the study; DNA was not available for 16 patients and DPYD sequencing was unsuccessful (poor quality score) for 27 patients (Fig 1, CONSORT Diagram). Thus, a total of 243 patients were included in the present analysis (12 recruiting centers). Inclusion criteria were women above 18-years-old with histologically-proven advanced breast cancer starting capecitabine treatment alone or in combination with anti-angiogenic therapy, whatever previous metastatic treatment lines were delivered, provided they did not include a fluoropyrimidine. Previous adjuvant treatment with fluoropyrimidine was allowed. Exclusion criteria included concomitant chemotherapy or lapatinib therapy, uncontrolled brain metastasis, uncontrolled chronic illness or infection, life expectancy lower than 3 months, cardiac failure or hypoxic respiratory failure. Capecitabine treatment was administered orally in two daily doses for 14 days, followed by 7 days off (day 1 = day 21). The capecitabine dose was left to the discretion of the physician. One to 15 days before starting treatment, 15 ml of blood were taken in the morning (8 am—11 am) for U and UH2 plasma analysis and DPYD genotyping. Toxicity (CTCAE v3 criteria) was assessed over cycles 1–2 (up to 21 days after the end of the 2nd cycle) in 242 patients.

**Biological analyses**

**DPYD sequencing.** DNA from total blood (10 ml) was extracted in one out of the 7 participating laboratories according to local routine procedures. DNA (1 μg required for DPYD sequencing) was sent to Integragen (Evry, France) where sequencing was performed. The 23 exons of DPYD gene, along with flanking intronic regions (20 bp), 3’UTR and part of 5’UTR
(580 bp upstream transcription initiation) were sequenced on MiSeq Illumina (PCR multiplex, 2x150 nt paired-end sequencing). Amplicons were sequenced in both directions. Obtained sequences were mapped to the human reference assembly genome HG19 and variant calling was performed on the NM_000110 reference transcript. SNPs alignment and variant calling were performed with the Illumina pipeline CASAVA1.8 using ELANDv2 algorithm. On average, 97% of target sequences were successfully covered with a mean depth at 1200X. Validated DNA samples passed quality scores (Q30 quality filter >90%, depth >15X). Indels were identified using the SNAP/GATK pipeline [26]. Local realignment, base recalibration and haplotype caller were performed using the GATK tool. INDELs with a quality score >50 and a depth >10X were selected. Pairwise linkage disequilibria (LD) between bi-allelic DPYD variants were measured by D’ and D'/LOD calculated on Haploview software v4.2.

In silico functional prediction. In silico pathogenicity prediction of coding variants was performed with the UMD-Predictor system [27]. Impact of exonic and intronic variations on splicing signal types was predicted with the Human Splicing Finder system [28].

DPD phenotyping

Blood (5 ml) was immediately placed in an ice-bath, centrifuged at +4°C for 15 min and frozen plasma was stored at -80°C. In order to mimic routine DPD-deficiency screening and ensure robustness, frozen plasmas were sent to one of 3 measuring laboratories (according to geographic location). Depending on the laboratory, solid-phase or liquid-liquid extraction followed by HPLC analysis (UV detection) of uracil (U) and dihydrouracil (UH2) was performed [29–31]. Limit of quantification was 7 to 25 ng/ml for UH2 and 3 to 6 ng/ml for U, depending on the laboratory. A common external quality control (N = 52 aliquots) was shared across the
3 laboratories. For UH2, 100% of control values were within +/- 15% of the mean value (92.2 ng/ml) and for U 98% of control values were within +/- 15% of the mean value (7.9 ng/ml) with one control value at +22%. Regarding the UH2/U ratio, 94% of control values were within +/- 15% of the mean value (11.7 ng/ml), with 3 values at -25%, -19% and +19%, respectively. Possible influence of measuring laboratories and recruiting centers on U and UH2/U concentrations was checked. Plasma U and UH2/U from patients were not significantly different between measuring laboratories. In contrast, comparison between recruiting centers showed that, in one institution U and UH2/U from patients differed significantly from other institutions (ANOVA tests: p < 0.001 for both U and UH2/U), suggesting a pre-analytical deviation. In order to accurately examine the impact of DPYD variants on U and UH2/U plasma concentrations, we excluded phenotype data from this recruiting center. In total, two hundred and five patients with validated DPYD sequencing were thus considered for phenotype analysis.

Statistics

The initial required number of 300 patients was based on the hypothesis that 35% of “at-risk patients” will develop grade 3–4 capecitabine-related toxicity versus 12% in the group of patients without risk (unilateral test, alpha = 0.05, beta = 0.10, relative risk = 2.9), with “at-risk patients” defined as those exhibiting a DPD-deficient phenotype. Hypothesis for DPD-deficient phenotype was UH2/U below 15th percentile or U above the 85th percentile. Considering patients with validated phenotyping data, actual study power was able to detect a relative risk (RR) of 3.50. The influence of each individual variant on DPD phenotype and capecitabine-related toxicity was assessed for DPYD variants present in at least 3 patients, using the non-parametric Mann-Whitney test and the Fisher Exact test, respectively. DPYD genotypes were considered as binary variables (wt/wt vs wt/var+var/var). Capecitabine-related toxicity included hematotoxicity, digestive toxicity and neurotoxicity. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and relative risk (RR) associated with DPD-deficiency screening approaches were computed. Sensitivity is defined as the proportion of patients found to be positive for DPD-deficiency among those experiencing toxicity. Specificity is defined as the proportion of patients without DPD-deficiency among those without toxicity. PPV is defined as the proportion of patients experiencing toxicity among those positive for the test. NPV is defined as the proportion of patients without toxicity among those negative for the test. RR is defined as the ratio of the toxicity risk in patients positive for the test to that in patients negative for the test. For the approach combining genotype and phenotype, we considered positivity of either one of the two approaches. All tests were two-sided and were not corrected for multiple testing. All p values ≤ 0.05 were reported. Statistics were performed on SPSS software (v15).

Results

Patient characteristics and toxicity

Table 1 describes patients’ characteristics. Mean age was 61.2 years (range 30–88), 88.5% of patients received capecitabine as monotherapy. Mean capecitabine dose at cycle 1 was 1942 mg/m²/day (median 1964, range 65–2590). Capecitabine-related digestive toxicity, hematotoxicity and neurotoxicity, grade (G) 3–4 was observed in 12.4% of patients (30 patients), and G4 was observed in 5 patients (2.1%), including one toxic death (S1 Table). Hand-foot syndrome G3 was observed in 9.5% of patients (no G4). Toxicity was not related to PS status, patient age, renal function (creatinine clearance), capecitabine treatment line, previous adjuvant fluoropyrimidine treatment, or capecitabine dose at first cycle. Table 2 details the profile of patients presenting G4-5 toxicity. A patient with toxic death (80-year-old) presented...
presented G4 thrombopenia, G4 diarrhea, G4 renal failure, G5 dyspnea and hypovolemic shock, 20 days after starting capecitabine monotherapy. This patient had lung and cutaneous metastases (PS 0, history of arterial hypertension), exhibited uracilemia at 16.7 ng/ml, UH2/U ratio at 6.5, was heterozygous for D949V polymorphism and carried 2 other variations in DPYD 3'UTR.

### Description of DPYD variants (Table 3)

A total of 65 DPYD variants were identified: 2 SNPs and one INDEL deviated from the Hardy-Weinberg equilibrium (p<0.07) and 8 SNPs showed poor quality scores or insufficient depth reading. In total, 54 variants (48 SNPs, 6 INDEL) were validated (mean call rate 98.9%). Fifteen variants were located at intron 5 (with one SNP and one insertion at same locus 98185720). Minor allele frequencies (MAF) ranged from 0.2% to 39.7% and were close to those already

| Performance status | N   | %     |
|--------------------|-----|-------|
| 0                  | 78  | 32.1  |
| 1                  | 65  | 26.7  |
| 2                  | 21  | 8.6   |
| 3                  | 4   | 1.6   |
| Unknown            | 75  | 30.9  |

| Previous adjuvant fluoropyrimidine | N   | %     |
|-----------------------------------|-----|-------|
| No                                | 153 | 63%   |
| Yes (5FU/capecitabine)            | 90  | 37%   |

| Metastasis site*                  | N   | %     |
|-----------------------------------|-----|-------|
| Bone                              | 161 | 66.3  |
| Liver                             | 127 | 52.3  |
| Lung                              | 95  | 39.1  |
| Lymph node                        | 62  | 25.5  |
| Cutaneous                         | 32  | 13.2  |
| Brain                             | 9   | 3.7   |
| Others                            | 12  | 4.9   |

| Capecitabine treatment            | N   | %     |
|-----------------------------------|-----|-------|
| Monotherapy                       | 215 | 88.5  |
| Concurrent bevacizumab            | 18  | 7.4   |
| Concurrent trastuzumab            | 7   | 2.9   |
| Concurrent lapatinib**            | 3   | 1.2   |

| Capecitabine line                 | N   | %     |
|-----------------------------------|-----|-------|
| 1<sup>st</sup> line               | 70  | 28.8  |
| 2<sup>nd</sup> line               | 87  | 35.8  |
| 3<sup>rd</sup> line               | 61  | 25.1  |
| ≥ 4<sup>th</sup> line             | 25  | 10.3  |

| Number of Capecitabine cycles     | N   | %     |
|-----------------------------------|-----|-------|
| ≥ 1 cycle                         | 243 | 100   |
| ≥ 2 cycles                        | 224 | 92.2  |
| ≥ 3 cycles                        | 208 | 85.6  |

* sum greater than 243 patients due to multiple metastases sites.

** these 3 patients (protocol violation) were kept in final analysis (none developed hematotoxicity, one developed digestive toxicity (grade 2) and 2 developed cutaneous toxicity (grade 3)).

https://doi.org/10.1371/journal.pone.0175998.t001
reported in Exome Variant Server (build Exome Sequencing Project 6500SI-V2-SSA137) or HapMap3 (CEU population) databases. The number of variant alleles per patient varied from 0 (8 patients) to 16 (median 3, mean 4, Q1-Q3: 2–5).

In total, 17 novel variations not identified in the dbSNP 141 database were observed (11 SNPs and the 6 INDELs, with MAF comprised between 0.2% and 2.1%). The six observed INDEL variations were all located in flanking intronic regions (intron 1, 5 and 13). The location of the 48 SNPs was as follows: 3 SNPs in 5'UTR; 19 SNPs in coding regions (4 synonymous including E412E and 15 missenses, including previously reported D949V, V732I, R592W, I560S, I543V, S492L, M406I, D342G, M166V, T65M, C29R and 3 novel variations A26T, F100L, R696H, each observed in one heterozygous patient); 19 SNPs in flanking intronic regions (including 2A, with no additional splicing variant) and 7 SNPs in 3'UTR. Consensual SNP *2A, D949V and I560S were carried by 7 patients (2.9%, all heterozygous).

Table 2. Profile of patients with grade 4–5 toxicity.

|                     | Patient #1 | Patient #2 | Patient #3 | Patient #4 | Patient #5 |
|---------------------|------------|------------|------------|------------|------------|
| Toxicity*           | Toxic death** (cycle 1) | G4 anemia | G4 thrombopenia G3 neutropenia (cycle 1) | G4 neurotoxicity (cycle 1) | G4 diarrhea (cycle 2) |
| Mean capecitabine dose intensity at cycle 1 (mg/ m²/day) | 1530 | 2030 | 1790 | 2490 | 2170 |
| PS at inclusion     | 0          | 1          | na         | 2          | 0          |
| Pre-treatment UH2/U | 6.5        | 14.0       | 13.5       | na         | na         |
| Pre-treatment U     | 16.7       | 12.9       | 22.0       | na         | na         |

** DPYD variants

| Variant   | 1530 | 2030 | 1790 | 2490 | 2170 |
|-----------|------|------|------|------|------|
| c.-477T>G | wt/wt | wt/wt | VAR/wt | wt/wt | wt/wt |
| C29R      | wt/wt | wt/wt | VAR/wt | wt/wt | wt/wt |
| F100L     | wt/wt | wt/wt | wt/wt | VAR/wt | wt/wt |
| c.483+837A>G §| wt/wt | wt/wt | VAR/wt | wt/wt | wt/wt |
| c.1129-15T>C §| wt/wt | wt/wt | VAR/wt | wt/wt | wt/wt |
| S492L     | wt/wt | wt/wt | wt/wt | VAR/wt |
| D949V     | VAR/wt | wt/wt | wt/wt | wt/wt | wt/wt |
| c.*274T>C §§| wt/wt | VAR/VAR | wt/wt | wt/wt | wt/wt |
| c.*432T>A | wt/wt | wt/wt | VAR/wt | wt/wt | wt/wt |
| c.*768G>A §§| VAR/VAR | VAR/VAR | VAR/VAR | wt/wt |
| c.*780C>T §§| VAR/wt | VAR/VAR | VAR/wt | wt/wt |

* All grade 3–4 toxicities.
** See Results section for details.
§ these 5 variants were in linkage disequilibria (see S2 Fig).
§§ these 3 variants were in linkage disequilibria (see S2 Fig).
na means not available.
These 5 patients all received capecitabine as monotherapy.

https://doi.org/10.1371/journal.pone.0175998.t002

In total, 17 novel variations not identified in the dbSNP 141 database were observed (11 SNPs and the 6 INDELs, with MAF comprised between 0.2% and 2.1%). The six observed INDEL variations were all located in flanking intronic regions (intron 1, 5 and 13). The location of the 48 SNPs was as follows: 3 SNPs in 5'UTR; 19 SNPs in coding regions (4 synonymous including E412E and 15 missenses, including previously reported D949V, V732I, R592W, I560S, I543V, S492L, M406I, D342G, M166V, T65M, C29R and 3 novel variations A26T, F100L, R696H, each observed in one heterozygous patient); 19 SNPs in flanking intronic regions (including *2A, with no additional splicing variant) and 7 SNPs in 3'UTR. Consensual SNP *2A, D949V and I560S were carried by 7 patients (2.9%, all heterozygous).
Table 3. Description of *DPYD* variations along with *in silico*/*in vitro* functionality.

| SNP or INDEL position (or rs if any) | Nucleotide change and nomenclature alias (if any) | Location | AA change | *In silico* functionality prediction (impact on splicing signal) | *In vitro* functionality [15]/[16] | wt/wt | Case number var/wt | MAF (%) | Significant association with deficient phenotype* | Significant association with increased toxicity** |
|-------------------------------------|--------------------------------------------------|----------|-----------|---------------------------------------------------------------|-----------------------------------|-------|-------------------|---------|-----------------------------------------------|-----------------------------------------------|
| rs145438244                         | c.-672T>C                                        | 5-UTR    |           |                                                               |                                   | 0.2   | nt                |         |                               |                                |
| rs56276561                          | c.483+16G>A                                      | Intron 5 |           | (No impact on splicing)                                       |                                   | 0.8   | NS                |         |                               |                                |
| rs98205969                          | c.300C>A                                         | Exon 4   | F100L     | Pathogenic (ESE site broken)                                  | F100[FS] very deficient / -        | 0.2   | na, nt            |         |                               |                                |
| rs55684412                          | c.483+837A>G                                     | Intron 5 |           | (No impact on splicing)                                       |                                   | 10.3  | NS                |         |                               |                                |

*Note: Additional rows are not shown in this excerpt.*
| SNP or INDEL position (or rs if any) | Nucleotide change and nomenclature alias (if any) | Location | AA change | In silico pathogenicity prediction (impact on splicing signal) | In vitro functionality [15] [16] | wt/wt | Case number | var/wt | var/var | MAF (%) | Significant association with deficient phenotype* | Significant association with increased toxicity** |
|-----------------------------------|-------------------------------------------------|----------|-----------|---------------------------------------------------------------|---------------------------------|-------|-------------|--------|--------|---------|------------------------------------------------|-------------------------------------------------|
| rs2297595                         | c.496A>G                                         | Exon 6   | M166V     | Benign (New ESS site and cryptic acceptor splice site)        | Proficient / Slightly deficient | 198   | 42          | 3      | 9.9    | NS      | NS                                             |                                                 |
| 98060744                          | c.851-22T>C                                      | Intron 8 | (No impact on splicing)                                     |                                 | 241   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
| rs183385770                       | c.1025A>G                                        | Exon 10  | D342G     | Pathogenic (ESE site broken, new ESS site)                    | D342N very deficient / -        | 241   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
| 98058849                          | c.1053T>C                                        | Exon 10  | A351A     | Benign (No impact on splicing)                                |                                 | 241   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
| 98058804                          | c.1098C>T                                        | Exon 10  | G366G     | Probably pathogenic (New ESS site)                           |                                 | 241   | 1           | 0      | 0.2    | na, nt  | nt                                             |                                                 |
| rs56293913                        | c.1129-15T>C                                     | Intron 10| (No impact on splicing)                                     |                                 | 191   | 46          | 5      | 11.6   | NS      | NS                                             |                                                 |
| rs61622928                        | c.1218G>A                                        | Exon 11  | M406I     | Benign (No impact on splicing)                                | Benign / Benign                | 242   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
| rs56038477                        | c.1236G>A                                        | Exon 11  | E412E     | Benign (No impact on splicing)                                |                                 | 239   | 4           | 0      | 0.8    | NS      | NS                                             |                                                 |
| rs72549304                        | c.1475C>T                                        | Exon 12  | S492L     | Pathogenic (New ESS site)                                     | Very deficient / -             | 241   | 1           | 0      | 0.2    | na, nt  | nt                                             |                                                 |
| rs199469537                       | c.1524+16C>A                                     | Intron 12| (No impact on splicing)                                     | -                              | 241   | 1           | 0      | 0.2    | na, nt  | nt                                             |                                                 |
| rs1801158                         | c.1601G>A (*4)                                   | Exon 13  | S534N     | Probably benign (New ESS site)                               | - / Slightly deficient         | 234   | 8           | 0      | 1.7    | NS      | NS                                             |                                                 |
| rs1801159                         | c.1627A>G                                        | Exon 13  | I543V     | Benign (No impact on splicing)                                | - / Benign                     | 161   | 73          | 8      | 18.4   | NS      | NS                                             |                                                 |
| rs55886062                        | c.1679T>G (*13)                                  | Exon 13  | I560S     | Pathogenic (No impact on splicing)                           | Very deficient / -             | 242   | 1           | 0      | 0.2    | na, nt  | nt                                             |                                                 |
| 97981200                          | c.1740+82del                                     | Intron 13| (No impact on splicing)                                     |                                 | 242   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
| rs59086055                        | c.1774C>T                                        | Exon 14  | R592W     | Pathogenic (New ESS site)                                     | Very deficient / -             | 241   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
| rs17376848                        | c.1896T>C                                        | Exon 14  | F632F     | Benign (New ESS site)                                        |                                 | 227   | 15          | 1      | 3.5    | NS      | NS                                             |                                                 |
| rs3918290                         | c.1905+1G>A (*2A)                                | Splice intron 14 | Pathogenic (Alteration of the donor site) | Very deficient / - | 240 | 3 | 0 | 0.6 | Yes | Yes | 
| rs369990607                       | c.1905+17A>G                                    | Intron 14 | (No impact on splicing)                                    |                                 | 242   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
| rs12078940                        | c.1906-24G>A                                    | Intron 14 | (No impact on splicing)                                    |                                 | 241   | 1           | 0      | 0.2    | nt      | nt                                             |                                                 |
Table 3. (Continued)

| SNP or INDEL position (or rs if any) | Nucleotide change and nomenclature alias (if any) | Location | AA change | In silico pathogenicity prediction (impact on splicing signal) | In vitro functionality [15]/[16] | wt/ wt | Case number var/wt | var/ var | MAF (%) | Significant association with deficient phenotype* | Significant association with increased toxicity** |
|-------------------------------------|-------------------------------------------------|----------|-----------|---------------------------------------------------------------|---------------------------------|--------|-------------------|---------|---------|-----------------------------------------------|-------------------------------------------------|
| 97771825                           | c.2087G>A                                        | Exon 17  | R696H     | Probably pathogenic (No impact on splicing)                   | - / -                           | 241    | 1                 | 0       | 0.2     | nt                                            | nt                                               |
| rs55846082                         | c.2179+28C>T                                     | Intron 17| (No impact on splicing)                                   | 241    | 1                 | 0       | 0.2     | nt                                            | nt                                               |
| rs138637410                        | c.2179+29G>A                                     | Intron 17| (No impact on splicing)                                   | 241    | 1                 | 0       | 0.2     | na, nt                                        | nt                                               |
| rs1801160                          | c.2197G>A (*6)                                    | Exon 18  | V732I     | Benign (No impact on splicing)                                | V732G benign / V732I Slightly deficient | 226    | 16                | 0       | 3.3     | NS                                            | NS                                               |
| rs67376798                         | c.2846A>T                                        | Exon 22  | D949V     | Probably pathogenic (ESE site broken, new ESS site)          | Moderately deficient / Moderately deficient | 240    | 3                 | 0       | 0.6     | Yes                                           | Yes                                              |
| rs56160474                         | c.*274T>C                                        | 3-UTR    |           |                                                              | 158    | 75                | 9       | 19.2    | NS                                            | NS                                               |
| rs188501488                        | c.*432T>A                                        | 3-UTR    |           |                                                              | 240    | 2                 | 0       | 0.4     | nt                                            | nt                                               |
| rs291592                           | c.*768G>A                                        | 3-UTR    |           |                                                              | 85     | 122               | 35      | 39.7    | NS                                            | NS                                               |
| rs291593                           | c.*780C>T                                        | 3-UTR    |           |                                                              | 151    | 78                | 13      | 21.5    | NS                                            | NS                                               |
| rs17470762                         | c.*900T>C                                        | 3-UTR    |           |                                                              | 222    | 19                | 1       | 4.3     | NS                                            | NS                                               |
| rs41285690                         | c.*1062A>G                                       | 3-UTR    |           |                                                              | 238    | 4                 | 0       | 0.8     | NS                                            | NS                                               |
| 97543343                           | c.*1189G>A                                       | 3-UTR    |           |                                                              | 241    | 1                 | 0       | 0.2     | nt                                            | nt                                               |

SNP and INDEL positions are given relative to genome build 37 HG19 (reference = nucleotide A of the translation initiation codon ATG).

In silico pathogenicity of coding variants was predicted using UMD-Predictor system [27]. The potential impact of exonic and intronic variations on splicing signal types was predicted using Human Splicing Finder system [28].

In vitro functionality derived from two published in vitro functional studies [15,16] reporting DPD enzyme activity of missense DPYD variants transgenically expressed in mammalian cells. In both studies, deficiency and proficiency were based on statistical comparison relative to wild-type DPD activity (100% activity). p value considered statistically significant was 0.05 in the study by Offer [15] and 0.001 in the study by van Kuilenburg [16]. Statistically significant DPD deficiency was classified as “Very deficient” for DPD activity ≤25% wild-type DPYD, “Moderately deficient” for DPD activity within 25–60% that of wild-type, and “Slightly deficient” for DPD activity >60% that of wild-type. Otherwise, variant functionality was considered benign (not statistically significant) or proficient when significantly greater than that of wild-type.—means that the variant was not tested in vitro.

MAF means minor allelic frequency, expressed as a percentage.
* Impact of each DPYD variation on phenotype (UH2/U or U) was tested by means of non-parametric Mann-Whitney test for variants present in at least 3 patients (see Statistics section and Fig 2 for details).
** Impact of each DPYD variation on digestive/hemato/neurotoxicity (grade 3-4-5 or grade 4–5) was tested by means of Fisher Exact test for variants present in at least 3 patients (see Statistics section).
*** Patients bearing variant allele C29R significantly experienced less toxicity than wt patients (p = 0.041).
* Variant linked to haplotype B3 comprising synonymous variant E412E and three intronic variants c.483+18G>A, c.680+139G>A and c.959-51T>C.
ESE means exonic splicing enhancer; ESS means exonic splicing silencer.
nt means not tested due to scarcity of variant carriers (less than 3 patients bearing at least one variant allele).
na means that DPD phenotype was not available (lack of validated UH2/U or U plasma concentration).
NS means not significant (p>0.05).
Yes means that a significant relationship (p<0.05) was observed (see details in the Results section).

https://doi.org/10.1371/journal.pone.0175998.t003
The location of the 19 observed exonic variants relative to DPD protein structure is shown in S1 Fig. Of note, F100L was located within the N-terminal Fe-S cluster containing the alpha helical domain I (Fig 2). No large intragenic deletion in the *DPYD* gene was observed by multiplex ligation-dependent probe amplification in the 30 patients with G3-4 toxicity (unshown data).

Analysis of pairwise linkage disequilibrium (LD) between the 52 bi-allelic variants (located at different loci) showed that mainly 2 regions were prone to LD: one restricted to 3’UTR and a second large region ranging from intron 5 till exon 11 (S2 Fig). This second region included c.483+18G>A and E412E that composed haplotype B3 (HapB3), along with 5 other linked SNPs (c.483+837A>G, c.483+1342T>A, c.483+1344T>A, M166V, c.1129-15T>C). HapB3 inference was highly likely for the 4 patients bearing E412E variant since they also exhibited the c.483+18G>A variation (all heterozygous).

For the 19 exonic SNPs, results of *in silico* pathogenicity (deficiency) prediction showed 7 variants predicted as pathogenic (including novel variants A26T and F100L), 3 as probably pathogenic (including novel variant R696H), and 9 as benign or probably benign (*Table 3*).

**Table 3** also depicts *in vitro* functionality reported in the literature [15,16] for known missense *DPYD* variations. D342G was not tested *in vitro* but codon 342 variation D342N was very deficient *in vitro*. Codon 100 variation F100[FS] was previously associated with loss of enzyme activity *in vitro*. A discrepancy was observed between *in silico* and *in vitro* functionality for variant T65M (proficiency not assessable by means of the UMD-Predictor tool).

**Association between *DPYD* variants and DPD phenotype**

For the 205 patients with validated phenotypic data, mean pre-treatment plasma UH2/U ratio was 11.1 (median 10.6, Q1-Q3 8.2–12.9, range 0.1–36) and mean plasma U was 10.9 ng/ml (median 9.6, Q1-Q3 7.7–12.2, range 3.9–75.3). The sum of variant alleles did not impact UH2/U or U concentrations. **Fig 3** illustrates the distribution of UH2/U and U plasma concentrations according to *DPYD* variants with very deficient (R592W, *2A, related-D342*N) or moderately deficient (D949V) enzyme activity *in vitro*, as well as M166V and HapB3. Only variant *2A and D949V were associated with a low UH2/U ratio (p = 0.039 and 0.008, respectively). Only variant D949V was associated with an elevated U concentration (p = 0.005).

**Association between *DPYD* variants and toxicity**

Analysis of the impact of each individual *DPYD* variant on toxicity showed that only variant D949V and *2A were significantly associated with an increased risk of developing grade 3–4 toxicity, with similar performance level: 66.7% (2/3) toxicity in wt/var patients vs 11.8% (28/239) in wt/wt patients (sensitivity 6.7%, specificity 99.5%, RR 5.69, 95%CI 2.38–13.6,
0.041). D949V and *2A variants had no significant impact when focusing on grade 4 toxicity. Of note, the only patient carrying the S492L allele and the patient carrying the F100L allele, both developed grade 4 toxicity (Table 2).

Predictive value of *DPYD* variants in combination was next examined (Table 4). The presence of one deficient allele among consensual variants *2A, D949V or I560S was significantly associated with grade 3–4 toxicity (sensitivity 16.7%, PPV 71.4%, RR 6.71, 95%CI 3.7–12.2, p < 0.001) but was not predictive of grade 4 toxicity. We then considered the 11 in silico pathogenic or probably pathogenic variants (*2A, *13, D949V, A26T, T65M, F100L, D342G, G366G, S492L, R592W, R696H). All these variants had very low MAF (<1%) and were only observed in heterozygous state. This set of 11 in silico deleterious variants was significantly associated with both grade 3–4 (sensitivity 26.7%, PPV 53.3%, RR 5.48, p < 0.001) and grade 4 hemato-digestive-neurotoxicity (sensitivity 60%, PPV 20%, RR 22.6, p = 0.002, Table 4).

Finally, we considered together variants *2A, D949V and I560S associated with all variants having shown very deficient (<25%) or moderately deficient (25–60%) in vitro enzyme activity.
Taking into account the 7 above-cited in vitro deleterious DPYD alleles (all mutually exclusive) improved the performance of the genotyping test relative to both the 3 consensual variants and the 11 in silico deleterious variants, on both grade 3–4 (sensitivity 26.7%, PPV 72.7%, RR 7.6, \( p < .001 \)) and grade 4 toxicities (sensitivity 60%, PPV 27.3%, RR 31.4, \( p = 0.001 \), Table 4).

In patients with validated phenotypic data, distribution of UH2/U was not different according to toxicity. In contrast, uracilemia was higher in patients developing grade 4 toxicity relative to patients who did not (Mann-Whitney test \( p = 0.016 \)). Patients with uracilemia above 14 ng/ml (i.e. 85th percentile = initial hypothesis) were significantly prone to develop grade 4 toxicity (Fisher Exact test \( p = 0.047 \)), however significance was not reached when regarding grade

| Tested biomarkers | Patients at risk | Grade 3–4 toxicity | Grade 4 toxicity |
|------------------|-----------------|-------------------|-----------------|
|                  | N total | Sens. | Spe. | PPV | NPV | RR (95%CI) | N event | Sens. | Spe. | PPV | NPV | RR (95%CI) | N event | p * |
| Three consensual variants (*2A, I560S, D949V)* | 2.9% (7/242) | 16.7% | 99.1% | 71.4% | 89.4% | 6.71 (3.69–12.2) | 12.4% (30) | <0.001 | 20% | 97.5% | 14.3% | 98.3% | 8.39 (1.07–65.7) | 2.1% (5) | 0.14 |
| Seven in vitro deleterious variants** | 4.6% (11/241) | 26.7% | 98.6% | 72.7% | 89.4% | 7.60 (4.44–13.0) | 12.4% (30) | <0.001 | 60% | 96.6% | 27.3% | 99.1% | 31.36 (5.8–168.9) | 2.1% (5) | 0.001 |
| Eleven in silico deleterious variants*** | 6.2% (15/241) | 26.7% | 96.7% | 53.3% | 90.3% | 5.48 (2.95–10.16) | 12.4% (30) | <0.001 | 60% | 94.9% | 20.0% | 99.1% | 22.6 (4.08–125.1) | 2.1% (5) | 0.002 |
| U > 16 ng/ml | 9% (18/203) | 12.5% | 91.6% | 16.7% | 88.6% | 1.47 (0.48–4.45) | 11.8% (24) | 0.45 | 66.7% | 92% | 11.1% | 99.5% | 20.56 (1.96–215.8) | 1.5% (3) | 0.021 |
| Combined U > 16 ng/ml and/or consensual variants* | 10.3% (21/203) | 20.8% | 91.1% | 23.8% | 89.6% | 2.28 (0.95–5.47) | 11.8% (24) | 0.082 | 66.7% | 90.5% | 9.5% | 99.5% | 17.33 (1.64–183.1) | 1.5% (3) | 0.029 |
| Combined U > 16 ng/ml and/or in vitro deleterious variants** | 10.9% (22/202) | 25.0% | 91.0% | 27.3% | 90.0% | 2.73 (1.21–6.14) | 11.9% (24) | 0.030 | 66.7% | 89.9% | 9.1% | 99.4% | 16.36 (1.55–173.2) | 1.5% (3) | 0.032 |

* The number of patients developing grade 3–4 toxicity among patients carrying DPYD variants was 2/3 for variant *2A, 1/1 for variant *13, 2/3 for variant D949V, 1/1 for variant F100L, 0/1 for variant D342G, 1/1 for variant S492L, 1/1 for variant R592W. All these variants were mutually exclusive.

** In vitro deleterious variants were *2A, I560S, D949V, F100L, D342G, S492L R592W (See Table 3 for details and literature references).

*** In silico deleterious variants were *2A, I560S, D949V, A26T, T65M, F100L, D342G, G366G, S492L, R592W, R696H (see Table 3 for details).

p value of the Fisher Exact test.

On this subset of 203 patients, association between either the presence of one variant among the 3 or 7 deleterious DPYD variants and grade 3–4 toxicity was confirmed (\( p = 0.002 \) and 0.001, respectively) but association with grade 4 toxicity was not.

Sens means sensitivity (% of patients positive for the tested biomarker among those experiencing toxicity), Spe means specificity (% of patients negative for the tested biomarker among those without toxicity), PPV means positive predictive value (% of patients experiencing toxicity among those positive for the tested biomarker), NPV means negative predictive value (% of patients without toxicity among those negative for the tested biomarker), RR means relative risk (ratio of the toxicity risk in patients positive for the tested biomarker to that in patients negative for the tested biomarker), NS means not significant.

https://doi.org/10.1371/journal.pone.0175998.t004
3–4 toxicity. Best uracilemia cutoff was 91st percentile: elevated uracilemia above 16 ng/ml was significantly associated with a RR of 20.6 to develop grade 4 toxicity (sensitivity 66.7%, PPV 11.1%, RR 20.6, p = 0.021) (Table 4). As compared with genotyping of either 3 consensual variants, or 7 in vitro deleterious, or 11 in silico deleterious variants, the combined genotype-phenotype approach (uracil > 16 ng/ml and/or the presence of deleterious DPYD allele) did not improve toxicity prediction. For instance, with the best combined approach (7 in vitro deleterious variants) sensitivity dropped from 26.7% to 25%, PPV from 72.7% to 27.3% and RR from 7.6 to 2.7 for grade 3–4 toxicity; for grade 4 toxicity sensitivity increased from 60% to 66.7%, and PPV dropped from 27.3% to 9.1% and RR from 31.4 to 16.4 (Table 4).

Discussion

Capecitabine can induce side-effects that not only impair quality of life and treatment efficacy but may also lead to life-threatening toxicity. Large studies have reported that capecitabine can induce 10% to 25% grade 3–4 digestive toxicity and/or hematotoxicity, 3–10% hand-foot syndrome and 0.2% to 0.6% lethal toxicity [12,22,23,32]. The present observational prospective study conducted on 243 breast cancer patients receiving capecitabine (monotherapy in majority) showed one lethal toxicity (0.4%), 12.4% grade 3–4 hemat/digestive/neurotoxicity and 9.5% grade 3 hand-foot syndrome, in line with literature data. For decades, DPD deficiency has been shown to be the main cause of severe and lethal fluoropyrimidine-related toxicity. Various analytical approaches have been developed for DPD-deficiency screening [33], including direct (PBMC enzyme activity) or indirect (measurement of pyrimidine metabolites) phenotyping, or DPYD genotyping. However, a still open question is how to faithfully identify patients at risk of toxicity. Our goal was to analyze exhaustive exome DPYD variations and examine their possible relationships with capecitabine-related toxicity and DPD phenotype assessed by pre-treatment plasma U or UH2/U concentrations, considered as a surrogate marker of DPD enzyme activity [29]. To our knowledge, this study is so far the largest prospective one reporting full DPYD exome sequencing in patients receiving fluoropyrimidine.

In total, DPYD sequencing revealed 54 variants, of which 19 exonic variations including 15 missenses (Table 3). In vitro functionality has already been reported for 11 presently-observed missense variations, with conflicting results for M166V variant only [15,16]. These two in vitro studies reported significantly severe reduced enzyme activity (≤25% relative to wild-type) for variants S492L, I560S, and R592W, moderate reduced activity (25–60% relative to wild-type) for variant D949V, while other variations showed either slight deficiency (>60% relative to wild-type) or no non-functional impact [15,16]. In line with in vitro data, variants I560S, R592W and S492L were predicted as pathogenic, and D949V was predicted as probably pathogenic, in silico. The presently-observed D342G variation has never been tested in vitro but D342N has been associated with very deficient enzyme activity [15]. For novel variant F100L, related in-frame 3-nucleotide insertion F100[FS] (rs72549301) at codon 100 has been associated with dramatic loss of activity in vitro [15]. Accordingly, D342G and novel F100L variations were predicted as pathogenic in silico. In total, these seven infrequent DPYD-deficient alleles (I560S, S492L, R592W, D342G, D949V, F100L and variant ‘2A) were observed at heterozygous status and were mutually exclusive in the present patient cohort.

Other DPYD variants of potential interest are those involved in Haplotype B3 (HapB3), highlighted as a significant predictor of fluoropyrimidine toxicity in a recent meta-analysis [19]. HapB3 comprised variant E412E, c.483+18G>A, and 2 other intronic variants not presently analyzed (c.680+139G>A, c.959-51T>G) [34]. HapB3 is also in tight linkage with the deleterious deep intronic variant c.1129-5923C>G [35]. Four patients carried the E412E allele (heterozygous) and were also the only ones to exhibit c.483+18G>A variation (heterozygous),
strongly suggesting that they carried HapB3. As concerns INDELs, the relevant duplication c.168_175dupGAATAATT in exon 3 (in silico pathogenic) identified in a DPD-deficient patient with lethal toxicity [31] was not found in the present patient cohort.

In complement to DPYD genotyping, we indirectly analyzed DPD phenotype by measuring physiological plasma U and UH2 concentrations, which is a more widely applicable approach than direct measurement of PBMC-DPD activity. Only *2A and D949V were significantly associated with DPD-deficient phenotype (I560S, S492L and F100L not tested due to lack of phenotype data) (Fig 3, Table 3). The single patient bearing R592W variant and the one carrying D342G, both expressed low UH2/U ratios. No clear link between phenotype and genotype emerged for HapB3 (4 heterozygous patients), nor for variant M166V (3 homozygous patients) (Fig 3). The patient with the most proficient phenotype (uracilemia 3.9 ng/ml) was heterozygous for variant I543V and for 3'UTR variant rs291592. The most deficient patient (uracilemia 75 ng/ml) was heterozygous for variant C29R, two 3'UTR variants (rs56160474, rs41285690) and one 5'UTR variant (rs61787828).

The main objective of this prospective study was to examine relationships between DPYD genotype and capecitabine-related toxicity. Consistent with phenotype data, single variant analyses revealed that only *2A and D949V were significantly associated with an increased risk of grade 3–4 digestive, hematotox or neuro-toxicities, in line with literature data [22]. The four HapB3 carriers did not present any trend for increased toxicity (no grade 3–4), in line with the results of a recent large prospective study conducted on 1228 5FU-treated patients [36]. The novel in silico pathogenic F100L variant was carried by a single patient who developed a grade 4 hematotoxicity associated with grade 3 neurotoxicity (Table 2). Interestingly, codon F100 is a very conserved residue located within the N-terminal 4Fe-4S cluster containing the alpha helical domain I of the enzyme (S1 Fig). This cluster plays an important role in the electron transfer responsible for the reduction reaction catalyzed by DPD enzyme (Fig 2). This clinical observation, along with in silico prediction and in vitro data reported for related-variant F100 [FS] [15], strongly suggests that infrequent variant F100L may be the causal origin of severe fluoropyrimidine-related toxicity.

Sensitivity of genotyping considering the 3 consensual variants *2A, D949V and I560S together was 16.7% for grade 3–4 toxicity (RR 6.7, p < 0.001) and was not significant on grade 4 toxicity (Table 4). In order to perform variant combinations as objectively as possible, two combination approaches were tested, one based on in silico prediction using the UMD-Predictor system [27], the other relying on existing in vitro functional data reporting DPD enzyme activity in transgenically-expressed missense DPYD variants [15,16]. The best performance was observed with the combined seven in vitro deleterious variants (Table 4). As compared to the 3 consensual variants, adding in vitro deleterious variants D342G, S492L, R592W and F100L increased the sensitivity to 26.7% for grade 3–4 toxicity, with a similar RR (7.6, p < 0.001). Moreover, the combination of the seven in vitro deleterious variants was significantly associated with grade 4 toxicity (sensitivity 60%, RR 31.4, p = 0.001) (Table 4). Present results show that extended DPYD genotyping to known in vitro deficient variants clearly improves the performance of consensual DPYD genotyping for pre-emptive identification of patients at-risk to develop severe fluoropyrimidine-related toxicities. An alternative strategy, although probably more time-consuming, may be to perform exome DPYD sequencing, and consider in silico prediction of coding variations. Even though the present study shows this latter approach to be less effective, both strategies deserve to be validated in a future prospective study.

Previous studies have suggested that pre-treatment plasma UH2/U or U is associated with fluoropyrimidine toxicity [30]. A recent large Dutch study [12] confirmed that pre-treatment plasma U is associated with global severe toxicity in patients receiving capecitabine. In the present patient cohort, pretreatment UH2/U ratio and uracil concentrations were not
significantly different between patients with or without grade 3–4 capecitabine toxicity (unshown data). However, patients presenting very high plasma U (>16 ng/ml, 91st percentile) were significantly prone to develop grade 4 toxicity relative to patients with U below 16 ng/ml (sensitivity 66.7%, RR 20.6, p = 0.021, Table 4). Finally, identifying at-risk patients based on either deficient phenotype (U >16 ng/ml) and/or deficient genotype did not substantially increase sensitivity as compared to genotype alone, while impairing toxicity predictive value and relative risk (Table 4). Present results suggest that the best approach for preventing grade 3–4 toxicity would be extended DPYD genotype, while prevention of more severe grade 4 toxicity may be based on plasma uracil only. The weak association between indirect DPD phenotyping (uracil, UH2/U) and grade 3–4 capecitabine-related toxicity may reflect the lack of correlation reported between PBMC-DPD enzyme activity and plasma UH2/U ratio, while a significant but weak correlation was observed between plasma U and PBMC activity [16]. This poor correlation between physiological pyrimidine concentrations and DPD enzyme activity may reflect the fact that, under low physiological U concentrations, DPD enzyme is not saturated, suggesting that only a marked DPD deficiency can impact physiological U and UH2 concentrations. Accordingly, literature data show that, in most cases, lethal toxicity is associated with a markedly deficient phenotype based on physiological pyrimidines in plasma [10,12,31], or enzyme activity [5]. In line, the lethal toxicity observed in the present study occurred in a patient presenting elevated U plasma concentration (above the 91st percentile). These observations fully justify the need to implement DPD-deficiency screening based on indirect or direct DPD phenotyping approaches for preventing lethal toxicities. An alternative possible relevant phenotyping approach is to explore uracil metabolism after administration of a loading dose of uracil that results in temporary DPD enzyme saturation [37,38]. Toxicity prevention of capecitabine-based chemotherapies may be improved by additional biomarkers linked to the regulation of DPD expression, such as miR-27a and more specifically MIR27A rs895819 polymorphism [39], or to polymorphisms in other genes related to capecitabine pharmacology, such as MTHFR, CDA, TYMS or ENOSF1 [40,41,42] that have been shown to be associated with capecitabine toxicity.

In conclusion, DPD-deficiency is recognized to be a leading cause of severe fluoropyrimidine toxicity [6,17] and a recent prospective study has demonstrated that fluoropyrimidine dose-adjustment based on upfront DPYD *2A genotyping (dose reduced by >50% in heterozygous carriers) was feasible, cost-effective, and improved safety [43]. Present results extend our understanding of deleterious DPYD variants and emphasize their potential impact on the toxicity of capecitabine-based treatments. A next step would be to establish whether upfront fluoropyrimidine dose-adjustment based on an extended DPD-deficiency screening approach could further improve safety without impairing treatment efficacy, while remaining cost-effective.

Supporting information

S1 Fig. Location of exonic DPYD variants relative to DPD protein.
(TIF)

S2 Fig. Pairwise linkage disequilibria (LD) between bi-allelic DPYD variants.
(TIF)

S1 Table. Description of maximal toxicity grade over cycles 1–2 (CTCAE v3 criteria).
(DOC)

Acknowledgments

This study was presented in part at the 2015 ASCO meeting (Chicago, USA).
Author Contributions

Conceptualization: MCEG JMF GM.

Data curation: MCEG JCB CB AVK YC EC.

Formal analysis: MCEG JCB CB LM AVK JPD DS AE YC EC.

Funding acquisition: MCEG JMF GM.

Investigation: CBD FT EC JLM FP CF JM LL.

Methodology: MCEG EC.

Project administration: GM.

Resources: GR PF TB XP VD RL MM AG HR JB VS ND JMF LC.

Software: CB LM YC EC.

Supervision: MCEG GM.

Validation: MCEG AVK.

Visualization: MCEG JCB CB LM.

Writing – original draft: MCEG JCB CB GM.

Writing – review & editing: MCEG JCB CB LM AVK CBD FT EC JLM FP CF JM AE LL GR PF TB XP VD RL MM AG HR JB VS ND YC EC JPD DS JMF GM LC.

References

1. Beck A, Etienne MC, Chéradame S, Fischel JL, Formento P, Renée N, et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer. 1994; 30A(10):1517–22. PMID: 7833111

2. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet. 2006; 21(5):357–74. PMID: 17072089

3. Fleming RA, Milano G, Thyss A, Etienne MC, Renée N, Schneider M, et al. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res. 1992; 52(10):2899–902. PMID: 1581906

4. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004; 40(7):939–50. https://doi.org/10.1016/j.ejca.2003.12.004 PMID: 15093568

5. Magné N, Etienne-Grimaldi MC, Cals L, Renée N, Formento JL, Francoual M, et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol. 2007; 64(2):237–40. PubMed Central PMCID: PMC2000632. https://doi.org/10.1111/j.1365-2125.2007.02869.x PMID: 17335544

6. Lunenburg CA, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JH et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016; 54:40–8. https://doi.org/10.1016/j.ejca.2015.11.008 PMID: 26716401

7. Etienne MC, Lagranges JL, Dassonville O, Fleming R, Thyss A, Renée N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol. 1994; 12(11):2248–53. https://doi.org/10.1200/JCO.1994.12.11.2248 PMID: 7964939

8. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995; 75(1):11–7. PMID: 7804963

9. Tuchman M, Stoeckeler JS, Kiang DT, O’Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med. 1985; 313(4):245–9. https://doi.org/10.1056/NEJM198507253130407 PMID: 2989687

10. Ciccolini J, Mercier C, Dahan L, Evrand A, Boyer JC, Richard K, et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase...
deficiency. Cancer Chemother Pharmacol. 2006; 58(2):272–5. https://doi.org/10.1007/s00280-005-0139-8 PMID: 16292536

11. Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res. 2006; 12(18):5496–502. https://doi.org/10.1158/1078-0432.CCR-06-0320 PMID: 17000685

12. Meulendijks D, van Hasselt JG, Huitema AD, van Tinteren H, Deenen MJ, Beijnen JH, et al. Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. Eur J Cancer. 2016; 54:120–30. https://doi.org/10.1016/j.ejca.2015.10.013 PMID: 26761784

13. Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salgueiro P, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998; 51(3):391–400. https://doi.org/10.1006/geno.1998.5379 PMID: 9721209

14. Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Mol Cancer Ther. 2014; 13(3):742–51. PubMed Central PMCID: PMC3954441. https://doi.org/10.1158/1053-7144.MCT-13-1087 PMID: 24403181

15. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropterydine dehydrogenase activity. Cancer Res. 2014; 74(9):545–54. PubMed Central PMCID: PMC4012613. https://doi.org/10.1158/0008-5472.CAN-13-2482 PMID: 24648345

16. van Kuilenburg AB, Meijer J, Tanck MW, Deenen MJ, Froehlich TK, Amstutz U, et al. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene. Biochim Biophys Acta. 2016; 1862(4):754–62. https://doi.org/10.1016/j.bbadis.2016.01.009 PMID: 26804652

17. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropterydine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013; 94(6):640–5. PubMed Central PMCID: PMC3831181. https://doi.org/10.1038/clpt.2013.172 PMID: 23988873

18. Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013; 14(11):1255–72. https://doi.org/10.2217/pgs.13.116 PMID: 23930673

19. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015; 16(6):1639–50.

20. Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014; 106(12). dju298. PubMed Central PMCID: PMC4271081. https://doi.org/10.1093/jnci/dju298 PMID: 25381393

21. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One. 2008; 3(12):e4003. PubMed Central PMCID: PMC2602733. https://doi.org/10.1371/journal.pone.0004003 PMID: 19104657

22. Deenen MJ, Tol J, Burlyo AM, Doedeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011; 17(10):3455–68. https://doi.org/10.1158/1078-0432.CCR-10-2209 PMID: 21498394

23. Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015; 64(1):111–20. PubMed Central PMCID: PMC4283622. https://doi.org/10.1136/gutjnl-2013-306571 PMID: 24647007

24. Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiadér CR. Clinical importance of risk variants in the dihydropterydine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015; 136(3):730–9. https://doi.org/10.1002/ijc.29025 PMID: 24923815

25. Milano G, Ferrero JM, Thomas F, Bobin-Dubigeon C, Merlin JL, Pinguet F, et al. A French prospective pilot study to identify dihydropterydine dehydrogenase (DPD) deficiency in breast cancer patients receiving capecitabine. San Antonio Breast Cancer Symposium 2013 (abst 179).

26. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20(9):1297–303. PubMed Central PMCID: PMC2928508. https://doi.org/10.1101/gr.107524.110 PMID: 20644199
27. Salgado D, Desvignes JP, Ra’i G, Blanchard A, Mitgen M, Pinard A, et al. UMD-Predictor: a High Throughput Sequencing Compliant System for Pathogenicity Prediction of any Human cDNA Substitution. Hum Mutat. 2016; 37(5):439–46. PubMed Central PMCID: PMC5067603. https://doi.org/10.1002/humu.22965 PMID: 26842889

28. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res. 2008; 36(11):3686–93. PubMed Central PMCID: PMC2585110. https://doi.org/10.1093/nar/gkp215 PMID: 19339519

29. Déporte R, Amiand M, Moreau A, Charbonnel C, Campion L. High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil/uracil ratio in plasma. J Chromatogr B Analyst Technol Biomed Life Sci. 2006; 834(1–2):170–7. https://doi.org/10.1016/j.jchromb.2006.02.046 PMID: 16545990

30. Boisdron-Celle M, Remaud G, Traore S, Poirier AL, Gamelin L, Morel A, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007; 249(2):271–82. https://doi.org/10.1016/j.canlet.2006.09.006 PMID: 17064846

31. Thomas F, Hennebelle I, Delmas C, Lochnan I, Dhelens C, Garnier Tixidre C, et al. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Clin Pharmacol Ther. 2016; 99(2):235–42. https://doi.org/10.1002/cpt.210 PMID: 26265035

32. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007; 25(1):102–9. https://doi.org/10.1200/JCO.2006.08.1075 PMID: 17194911

33. van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG. Evaluation of predic- tive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenomics J. 2013; 13(5):389–95. https://doi.org/10.1038/tpj.2013.25 PMID: 23856855

34. Amstutz U, Faraese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009; 10(6):331–44. https://doi.org/10.2217/pgs.09.28 PMID: 19530960

35. van Kuilenburg AB, Meijer J, Mul AN, Meinisma R, Schmid V, Dobritsch D, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet. 2010; 128(5):529–38. PubMed Central PMCID: PMC2955237. https://doi.org/10.1007/s00439-010-0879-3 PMID: 20803296

36. Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, et al. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenet Genomics. 2016; 26(3):133–7. PubMed Central PMCID: PMC4738010 [Available on 2017-03-01]. https://doi.org/10.1097/FPC.0000000000000197 PMID: 26558227

37. Ezzedlin HI, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB. (13)C-5-FU breath test current status and future directions: a comprehensive review. J Breath Res. 2009; 3(4):047002. https://doi.org/10.1088/1752-7155/3/4/047002 PMID: 21386199

38. van Staveren MC, van Kuilenburg AB, Duchelaar HJ, Meijer J, Punt CJ, de Jong RS, et al. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy. Br J Clin Pharmacol. 2016; 81(3):553–61. PubMed Central PMCID: PMC4767209 [Available on 2017-03-01]. https://doi.org/10.1111/bcp.12821 PMID: 26655158

39. Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clin Cancer Res 2015; 21:2038–44. https://doi.org/10.1158/1078-0432.CCR-14-2817 PMID: 25655103

40. Loganayagam A, Arenas Hernandez M, Corrigan A, Fairbanks L, Lewis CM, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer. 2013; 108:2505–15. PubMed Central PMCID: PMC3694243. https://doi.org/10.1038/bjc.2013.262 PMID: 23736036

41. Lam SW, Duchelaar HJ, Boven E. The role of pharmacogenetics in capecitabine efficacy and toxicity. Cancer Treat Rev 2016; 50:9–22. https://doi.org/10.1016/j.ctrv.2016.08.001 PMID: 27569869

42. Rosamarin D, Palle C, Pagamenta A, Kaur K, Pita G, Martin M, Domingo E, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015; 64:111–20. PubMed Central PMCID: PMC3694243. https://doi.org/10.1136/gutjnl-2013-306571 PMID: 24647007

43. Deenen MJ, Meulendijk S, Cats A, Sechtemerber MK, Severens JL, Boot H et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016; 34(3):227–34. https://doi.org/10.1200/JCO.2015.63.1325 PMID: 26573078